Kakimi K - Search Results

1

Exploring immune therapy for renal cancer.

Matsushita H, Kakimi K, Tomita Y, Tatsugami K, Naito S, Suekane S, Noguchi M, Moriya F, Matsuoka K, Itoh K, Kobayashi H, Eto M, Takahashi W, Kawano Y, Wada Y. Matsushita H, et al. Among authors: kakimi k. Int J Urol. 2011 Jun;18(6):412-21. doi: 10.1111/j.1442-2042.2011.02762.x. Int J Urol. 2011. PMID: 21599759 No abstract available.

2

[γδ T cell-based cancer immunotherapy].

Matsushita H, Kakimi K. Matsushita H, et al. Among authors: kakimi k. Nihon Rinsho. 2017 Feb;75(2):301-305. Nihon Rinsho. 2017. PMID: 30562868 Japanese.

3

[Dendritic cells for cancer immunotherapy].

Kakimi K, Kondo A, Matsushita H. Kakimi K, et al. Nihon Rinsho. 2012 Dec;70(12):2130-5. Nihon Rinsho. 2012. PMID: 23259385 Review. Japanese.

4

Advances in personalized cancer immunotherapy.

Kakimi K, Karasaki T, Matsushita H, Sugie T. Kakimi K, et al. Breast Cancer. 2017 Jan;24(1):16-24. doi: 10.1007/s12282-016-0688-1. Epub 2016 Mar 21. Breast Cancer. 2017. PMID: 27000871 Review.

5

γδ T cell therapy for the treatment of non-small cell lung cancer.

Kakimi K, Matsushita H, Murakawa T, Nakajima J. Kakimi K, et al. Transl Lung Cancer Res. 2014 Feb;3(1):23-33. doi: 10.3978/j.issn.2218-6751.2013.11.01. Transl Lung Cancer Res. 2014. PMID: 25806278 Free PMC article. Review.

6

Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma.

Matsushita H, Sato Y, Karasaki T, Nakagawa T, Kume H, Ogawa S, Homma Y, Kakimi K. Matsushita H, et al. Among authors: kakimi k. Cancer Immunol Res. 2016 May;4(5):463-71. doi: 10.1158/2326-6066.CIR-15-0225. Epub 2016 Mar 15. Cancer Immunol Res. 2016. PMID: 26980598

7

Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer.

Aoki T, Matsushita H, Hoshikawa M, Hasegawa K, Kokudo N, Kakimi K. Aoki T, et al. Among authors: kakimi k. Cytotherapy. 2017 Apr;19(4):473-485. doi: 10.1016/j.jcyt.2017.01.002. Epub 2017 Feb 7. Cytotherapy. 2017. PMID: 28188072 Clinical Trial.

8

Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.

Noji S, Hosoi A, Takeda K, Matsushita H, Morishita Y, Seto Y, Kakimi K. Noji S, et al. Among authors: kakimi k. J Immunother. 2012 Jul;35(6):460-72. doi: 10.1097/CJI.0b013e31826092db. J Immunother. 2012. PMID: 22735804

9

Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.

Karasaki T, Nagayama K, Kawashima M, Hiyama N, Murayama T, Kuwano H, Nitadori J, Anraku M, Sato M, Miyai M, Hosoi A, Matsushita H, Kikugawa S, Matoba R, Ohara O, Kakimi K, Nakajima J. Karasaki T, et al. Among authors: kakimi k. J Thorac Oncol. 2016 Mar;11(3):324-33. doi: 10.1016/j.jtho.2015.11.006. Epub 2015 Dec 29. J Thorac Oncol. 2016. PMID: 26752676 Free article.

10

Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma.

Kobayashi Y, Yamada D, Kawai T, Sato Y, Teshima T, Yamada Y, Nakamura M, Suzuki M, Matsumoto A, Nakagawa T, Hosoi A, Nagaoka K, Karasaki T, Matsushita H, Kume H, Kakimi K. Kobayashi Y, et al. Among authors: kakimi k. Int J Oncol. 2020 Apr;56(4):999-1013. doi: 10.3892/ijo.2020.4975. Epub 2020 Feb 4. Int J Oncol. 2020. PMID: 32319571

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

163 results

Search Page